cancer

UCLA xenograft research has the potential to change the way that people with sarcoma and other cancers are treated.

Software developed by a UCLA urologist helps men avoid decisions they might regret.

UCLA researchers found that with estrogen therapy for menopause, taking a pill versus wearing a patch on one’s skin doesn’t affect risk or benefit.

Catherine Carpenter of the UCLA Jonsson Comprehensive Cancer Center explains how a few small adjustments to your barbecuing protocol can reduce your exposure to carcinogens.

UCLA study shows that slow-moving meditation practice works just as well as talk therapy, and better than medication.

The findings lay the groundwork for developing new and improved combination therapies for patients who resistant to stand-alone immunotherapy.

Dr. Richard Finn led the clinical studies that led to the approval of regorafenib, which is used to treat hepatocellular carcinoma.

UCLA study identifies a potential test that may help select patients for whom it could be most effective.

Customized treatment plans are particularly important for lower-income women, who tend to have less access to high-quality health care.

Researchers from the Broad Stem Cell Research Center created a system to produce human T cells, the white blood cells that fight against disease-causing intruders in the body.

CancerLocator, developed by UCLA researchers, was superior in detecting cancer in blood samples containing low levels of target DNA, which reflect early-stage disease.

Dr. Zev Wainberg, a member of the UCLA Jonsson Comprehensive Cancer Center, sheds light on a handful of common misconceptions about the disease, which kills 50,000 Americans each year.

In this Q&A, UCLA’s Dr. Sara Hurvitz sheds light on the benefits of caps, how they work and if men could use them

UCLA researchers found that a combination therapy going after stem cells and chemotherapy resulted in better outcomes.

Every year as Californians file their state income taxes, they have an opportunity to help University of California researchers and others in the fight against cancer.

New recommendations are needed in part because people with cancer are living longer thanks to improved treatments, giving tumors more time to spread to other parts of the body.

UCLA-led study of DNA patterns in tumor cells suggests that the abundance of aberrant genetic signatures common in more aggressive cancers is not random.

UCLA researchers determined for the first time why some people with advanced melanoma or advanced colon cancer will not respond to pembrolizumab.

Researchers found that combining a vaccine developed at UCLA with two drugs that modulate distinct aspects of the immune system was more effective at allowing T cells to attack glioblastoma than the vaccine alone.

UCLA Jonsson Comprehensive Cancer Center researchers discuss the parallels — and the sometimes unexpected intersections between the two pursuits.

Dr. Edward Garon, UCLA Jonsson Comprehensive Cancer Center member and associate professor of hematology and oncology at the David Geffen School of Medicine, has received a new grant from the National Institutes of Health.

California State Senate will discuss barriers, such as difficult-to-navigate health system, inadequate insurance, and cultural misconceptions, as well as possible solutions Jan. 12.

UCLA-led research found people with advanced head and neck squamous cell carcinoma and a certain genetic mutation have improved survival when given a drug in combination with standard therapies.

UCLA researchers have found that Tianshengyuan-1 increased activity of an enzyme that plays a role in regulating cell division, which is a factor in treating blood cell deficiency and cancer.

Researchers from the schools of dentistry, medicine and engineering developed a digital health platform capable of optimizing efficacy and safety during chemotherapy.